ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares saw unusually-high trading volume on Monday . Approximately 228,885 shares changed hands during trading, an increase of 5% from the previous session’s volume of 218,944 shares.The stock last traded at $55.40 and had previously closed at $54.91.

ANIP has been the subject of a number of recent analyst reports. Oppenheimer Holdings Inc. reissued a “buy” rating and set a $49.00 price objective (up from $47.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, April 13th. Guggenheim restated a “buy” rating and set a $55.00 target price (up from $50.00) on shares of ANI Pharmaceuticals in a report on Saturday, May 7th. Standpoint Research cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 24th. Zacks Investment Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 6th. Finally, Citigroup Inc. cut ANI Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $49.00 target price for the company. in a report on Friday, July 8th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $57.88.

The company has a market capitalization of $648.66 million and a price-to-earnings ratio of 53.05. The stock’s 50-day moving average is $55.07 and its 200 day moving average is $42.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, May 5th. The specialty pharmaceutical company reported $0.76 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.12. The company earned $20.60 million during the quarter, compared to analysts’ expectations of $21.03 million. During the same quarter in the prior year, the company earned $0.57 earnings per share. The firm’s revenue was up 9.6% compared to the same quarter last year. On average, equities analysts expect that ANI Pharmaceuticals Inc. will post $3.67 earnings per share for the current fiscal year.

Several hedge funds recently modified their holdings of the stock. Mutual of America Capital Management LLC increased its stake in shares of ANI Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 30,178 shares of the specialty pharmaceutical company’s stock valued at $1,362,000 after buying an additional 178 shares in the last quarter. Deere & Co. acquired a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $1,961,000. Finally, GSA Capital Partners LLP raised its position in ANI Pharmaceuticals by 10.8% in the fourth quarter. GSA Capital Partners LLP now owns 55,447 shares of the specialty pharmaceutical company’s stock valued at $2,502,000 after buying an additional 5,420 shares during the last quarter.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.